Illumina, Inc. (ILMN)
| Market Cap | 41.33B +192.7% |
| Revenue (ttm) | 4.49B +4.9% |
| Net Income | 824.00M -34.4% |
| EPS | 5.37 -32.1% |
| Shares Out | 151.00M |
| PE Ratio | 50.96 |
| Forward PE | 48.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,939,287 |
| Open | 272.71 |
| Previous Close | 272.00 |
| Day's Range | 270.30 - 280.17 |
| 52-Week Range | 88.00 - 280.17 |
| Beta | 1.47 |
| Analysts | Buy |
| Price Target | 202.65 (-25.95%) |
| Est. Earnings | Oct 29, 2026 |
About ILMN
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price target is $202.65, which is a decrease of -25.95% from the latest price.
News
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of tradi...
Bloom Energy and These 2 Stocks Are Joining the S&P 500
The S&P 500 is getting three new members this month, with Bloom Energy, Everpure, and Illumina joining the benchmark as part of its latest quarterly reshuffle.
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Illumina Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue and EPS growth, driven by strong clinical demand, expanding NovaSeq X placements, and innovation in multi-omics and AI-enabled offerings. Full-year guidance was raised for revenue and EPS, with clinical markets and new products expected to drive future growth.
Illumina Earnings release: Q2 2026
Illumina released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Illumina Slides: Q2 2026
Illumina has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Illumina Quarterly report: Q2 2026
Illumina has published its Q2 2026 quarterly earnings report on July 30, 2026.
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 20...
Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown
CHICAGO--(BUSINESS WIRE)---- $ILMN #AI--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with instit...
Illumina expands Billion Cell Atlas program with new AI drug developers
Partners will use unprecedented data scale to advance more precise medicines to approval SAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell At...
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. O...
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the ap...
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc....
Illumina (ILMN): Bullish Structure Builds After Breakout
Illumina maintains a long-term bullish reversal after breaking out of an inverse head and shoulders pattern, with key support holding as upside targets remain in focus.
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can gener...
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN)...
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina's hi...
David P. King elected to Illumina's Board of Directors
Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's Board SAN DIEGO, May 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today confirmed th...
Illumina Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals preliminarily approved. No questions were submitted during the Q&A, and forward-looking statements were qualified by reference to SEC filings.
Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact
SAN DIEGO, May 19, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today published its annual Corporate Responsibility (CR) Report. The report highlights the company's continued progress in expandin...